Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA agrees to two pivotal protocols for pexelizumab

June 16, 2004

Teva and Active Biotech sign laquinimod licensing deal

June 16, 2004

Aptosyn phase III study in NSCLC fails to meet endpoints

June 16, 2004

Peripheral efficacious kappa opioid agonist with unprecedented selectivity

June 16, 2004

Phase I data on XR-5944 in patients with refractory advanced cancer

June 16, 2004

Preliminary data suggest epratuzumab plus rituximab is safe and effective in NHL

June 16, 2004

Increased survival achieved with efaproxiral in patients with brain metastases

June 16, 2004

Human serpin with potential to heal diabetic ulcers

June 16, 2004

Biliverdin protective against endotoxin-induced acute lung injury

June 16, 2004

Inhibitors of prostaglandin and leukotriene production developed at Wakamoto

June 15, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...